<table>
<thead>
<tr>
<th>CLINICAL DIRECTIVE 01/2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FROM:</strong> Medical Director</td>
</tr>
<tr>
<td><strong>TO:</strong> Paramedics, Advanced Paramedics</td>
</tr>
<tr>
<td><strong>SUBJECT:</strong> Use of Ticagrelor for STEMI patients</td>
</tr>
</tbody>
</table>

Ticagrelor is a new anti-platelet agent, similar in action to clopidogrel and has some advantages over clopidogrel. The HSE Acute Coronary Syndromes Programme, the Medical Advisory Committee of PHECC and the NAS Medical Directorate have agreed its use in place of clopidogrel under the following circumstances:

- The patient has a confirmed STEMI
- The patient has been accepted for PCI at a PPCI centre-administration of ticagrelor should be agreed in all cases with the receiving cardiologist by telephone.
- The dose is ticagrelor 180 mg (2 x 90 mg tablets)

STEMI patients not going for PCI (eg because transport time is > 90 minutes) should continue to receive clopidogrel as per CPG.

**RATIONALE:**
The Acute Coronary Syndrome Clinical Practice Guideline will issue shortly. This clinical directive authorises the use of ticagrelor until the CPG is published.

**EFFECTIVE FROM:**
February 12th 2014

**EFFECTIVE TO:**
ACS CPG published by PHECC

**QUESTIONS OR COMMENTS ON THIS DIRECTIVE:**
Education and Competency Assurance Officer

Clinical Directives are formulated by the National Ambulance Service Medical Directorate, the National Ambulance Service Education and Competency Assurance Team, the Dublin Fire Brigade Medical Director, the Dublin Fire Brigade EMS Support Team and the Irish Coast Guard Chief Crewman (Standards). Clinical Directives apply to all relevant staff in the HSE National Ambulance Service, Dublin Fire Brigade and Irish Coast Guard helicopter winch-crew.